Stay updated on SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial page.

Latest updates to the SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial page
- CheckyesterdayChange DetectedA banner announces NIH’s transition from the term “Artificial Intelligence” to “Super Intelligence.” The site revision label changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1. The page continues to show a 403 error instead of the study record.SummaryDifference0.2%

- Check29 days agoChange DetectedThe study page now shows a 403 Forbidden error, indicating the record is temporarily inaccessible. This reflects an access issue rather than a content update to the study details.SummaryDifference21%

- Check36 days agoChange DetectedRevision v3.7.0 was applied, replacing the previous v3.6.6. This indicates an update to the page framework or template rather than new or removed study information.SummaryDifference0.0%

- Check43 days agoChange DetectedPhase 2 Part C was not initiated and no participants were enrolled in that cohort, with the record noting Phase 1 completion and subsequent status updates.SummaryDifference1%

- Check50 days agoChange DetectedThe page revision label updated from v3.6.5 to v3.6.6. It indicates a newer page build rather than changes to the study information.SummaryDifference0.0%

Stay in the know with updates to SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial page.